NCT05816720View on ClinicalTrials.gov

Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

CompletedOBSERVATIONAL
Enrollment

31

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
Neuroendocrine Tumor
Interventions
DRUG

Lutetium-177 DOTATATE

Intravenous administration

Trial Locations (1)

77042

Excel Diagnostics & Nuclear Oncology Center, Houston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY